Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
about
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey modelEltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease.Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia.Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian ratsEmerging drugs for Parkinson's disease.Drug Insight: new drugs in development for Parkinson's disease.Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats.Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian ratsSerotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.The serotonergic system in motor and non-motor manifestations of Parkinson's disease.Advances in non-dopaminergic treatments for Parkinson's diseaseTherapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?Antidepressant-like properties of sarizotan in experimental Parkinsonism.Pre- and postsynaptic serotoninergic excitation of globus pallidus neurons.Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.5-HT(1A) receptor activation improves anti-cataleptic effects of levodopa in 6-hydroxydopamine-lesioned rats.Intramolecular carbolithiation of N-allyl-ynamides: an efficient entry to 1,4-dihydropyridines and pyridines - application to a formal synthesis of sarizotan.Potential cellular and regenerative approaches for the treatment of Parkinson's disease.Serotonin activates presynaptic and postsynaptic receptors in rat globus pallidus.Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.Therapy for dyskinesias in Parkinson’s disease patients
P2860
Q24646533-B6D77450-291B-416B-AF6A-8C440FE3465AQ27303857-0B889031-37FC-492C-BC88-91902A8C3E01Q33255884-062AA312-708E-4E94-91C6-B4F401CCB5DFQ34101796-262B4D7B-4D47-42FC-A2A4-9CB01D0097D8Q35000569-5BFDF400-4EA4-4DDD-9B21-B2706002BA16Q35038040-834ABD3C-A7C9-4710-BC6B-22B55F2AC7F0Q35087525-8FB9F3FF-A58E-4215-8E88-AD975C8F9C9FQ35614156-0EBB7CA8-DDFD-4958-A372-4F42C2E6E983Q36243814-496F04A7-517B-41B5-B4B4-694F8A35B092Q36580572-CE9E3197-2203-4809-9A4E-BD0F72193422Q36631654-0B50FD12-6383-42F7-949A-F5ACFC8ED98DQ36750148-1AC6539A-84E5-4579-8209-BCB515644DADQ36851672-9392C48D-3CE6-4AAB-98F5-05675659AB99Q37103028-0D6BDB69-13C6-4D70-9BC6-5594114A5D8FQ37341623-DCEC6527-4E4D-4BB2-980A-3183D40B706EQ37397245-5A0F78CF-063A-4CB5-BFF2-87A1164531BDQ37602233-11B4EE9C-33AD-4D7F-8A1B-2526926975FEQ38118061-AA522A42-7516-46D1-8B37-B58E05D0EB17Q38218083-897247BD-7C1F-4376-83FB-F8415E568C31Q38284574-9D99EDCC-F3CB-4590-95E4-7B46921DBF3CQ38951947-BB4D2CD5-1269-4FCA-89D5-5830414BAF7BQ39328856-0FF316C2-AACA-4D3D-9F4A-5E6236CA5713Q40081684-578A9386-FCAC-4AC6-B7B3-031843712E95Q40379397-A85A3CFD-038C-498F-8F4A-3C19AF54733AQ41902359-419D17E3-6257-41C4-8CC5-3E31880CA31AQ43058056-D63BC77A-CF0E-4F0D-8AEB-26C78545BEB1Q43198086-9D055A79-4985-42EC-A761-75B2ABFE63D1Q46782158-D5648EDB-0A1B-4AD8-9DC5-55ED48FCA40CQ48300577-443E854F-8499-4A80-A7A4-ED85CA03CC35Q53410082-72932437-B1F2-45AA-BCD8-1D999B004055Q57518128-2A5A0089-94EB-4AF4-B4FE-0A328C33F1C1
P2860
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
@ast
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
@en
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
@nl
type
label
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
@ast
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
@en
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
@nl
prefLabel
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
@ast
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
@en
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
@nl
P2093
P2860
P356
P1433
P1476
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease
@en
P2093
Abdullah Sherzai
Francesco Bibbiani
Michael J Morris
Thomas N Chase
Tzvetelina Dimitrova
William Bara-Jimenez
P2860
P304
P356
10.1002/MDS.20370
P407
P577
2005-08-01T00:00:00Z